Treats onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). ANDA 78199, held by Chartwell RX. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 78199 (Terbinafine Hydrochloride), held by Chartwell RX, was first approved by FDA on Jul 2, 2007, with 6 approved supplements and 0 published complete response letters.
Terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE ยท tablet;oral | Terbinafine Hydrochloride | Rx |
| Feb 28, 2020 | Supplement 11Labeling ยท Standard review | Approved | None posted |
| Feb 28, 2020 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Feb 28, 2020 | Supplement 9Labeling ยท Standard review | Approved | None posted |
| Aug 25, 2015 | Supplement 8Labeling ยท Standard review | Approved | None posted |
| Feb 19, 2013 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Jul 12, 2012 | Supplement 4Labeling | Approved | None posted |
| Jul 2, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters